{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["Q4-2023"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":0,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Q4-2023","index":0,"n_rows":116,"n_cols":9,"rows_kept":116,"cut":false,"hidden":false,"merged":[]}
["Therapeutic area","Project ","Phase ","NCT number ","Title","Conditions ","Enrollment","Study design","Dates"]
["Immuno-inflammation","frexalimab (anti-CD40L mAb)","\nPhase 2\n","NCT05039840","Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus","• Systemic Lupus Erythematosus",116,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 9, 2025\nStudy Completion: September 1, 2025"]
["Immuno-inflammation","itepekimab (anti-IL33 mAb)","\nPhase 3\n","NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)","• Chronic Obstructive Pulmonary Disease",1210,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 30, 2025\nStudy Completion: October 17, 2025"]
["Immuno-inflammation","itepekimab (anti-IL33 mAb)","\nPhase 3\n","NCT04701983","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/ Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)","• Chronic Obstructive Pulmonary Disease",960,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 27, 2025\nStudy Completion: November 28, 2025"]
["Immuno-inflammation","frexalimab (anti-CD40L mAb)","\nPhase 2\n","NCT04572841","Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)","• Sjögren's Syndrome\n• Sjogren's Syndrome",84,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: November 8, 2023\nStudy Completion: February 1, 2024"]
["Immuno-inflammation","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT04520451","Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Patients","• Immunoglobulin G4 Related Disease",27,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 30, 2024\nStudy Completion: September 27, 2024"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04456673","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","• Chronic Obstructive Pulmonary Disease",935,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 2024\nStudy Completion: August 2024"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","• Bullous Pemphigoid",106,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 16, 2024\nStudy Completion: January 7, 2025"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","• Chronic Spontaneous Urticaria",384,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 15, 2024\nStudy Completion: November 29, 2024"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT03560466","Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)","• Asthma",365,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2025\nStudy Completion: March 31, 2025"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT02612454","Study to Assess the Long-term Safety of Dupilumab Administered in Participants #6 Months to <18 Years of Age With Atopic Dermatitis (AD)","• Atopic Dermatitis",880,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 19, 2026\nStudy Completion: August 19, 2026"]
["Immuno-inflammation","eclitasertib (RIPK1 inhibitor)","\nPhase 2\n","NCT05588843","Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis","• Colitis Ulcerative",182,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: November 19, 2025\nStudy Completion: September 9, 2026"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT05526521","A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants\n#2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)","• Chronic Spontaneous Urticaria",24,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 1, 2025\nStudy Completion: July 7, 2025"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT05492578","Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials","• Dermatitis Atopic",450,"• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 29, 2027\nStudy Completion: April 18, 2028"]
["Immuno-inflammation","SAR447189 (anti-TL1A mAb)","\nPhase 2\n","NCT05499130","A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease","• Crohn Disease\n• Colitis, Ulcerative",240,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 16, 2024\nStudy Completion: January 15, 2025"]
["Immuno-inflammation","Rezurock (ROCK2 inhibitor)","\nPhase 3\n","NCT06082037","A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction","• Lung Transplant Rejection",180,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 17, 2026\nStudy Completion: June 2, 2028"]
["Immuno-inflammation","frexalimab (anti-CD40L mAb)","\nPhase 2\n","NCT06111586","FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)","• Type 1 Diabetes Mellitus",192,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: April 30, 2027\nStudy Completion: October 27, 2028"]
["Immuno-inflammation","lunsekimig (anti-IL13/TSLP Nanobody VHH)","\nPhase 2\n","NCT06102005","Dose Ranging Study of SAR443765 Compared With Placebo-control in Adult Participants With Moderate to Severe Asthma","• Asthma",630,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: June 30, 2026\nStudy Completion: June 30, 2026"]
["Immuno-inflammation","SAR441566 (TNFR1 signaling inhibitor)","\nPhase 2\n","NCT06073119","A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis","• Psoriasis",207,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 13, 2025\nStudy Completion: April 24, 2025"]
["Immuno-inflammation","SAR441566 (TNFR1 signaling inhibitor)","\nPhase 2\n","NCT06073093","A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis","• Rheumatoid Arthritis",240,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 13, 2025\nStudy Completion: August 8, 2025"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT06015308","A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo","• Dermatitis Atopic",166,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: April 28, 2025\nStudy Completion: August 18, 2025"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\n• Phase 2\n• Phase 3\n","NCT05831176","A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis","• Eosinophilic Gastritis\n• Eosinophilic Duodenitis\n• Eosinophilic Gastrointestinal Disease",279,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 19, 2027\nStudy Completion: August 19, 2027"]
["Immuno-inflammation","SAR447189 (anti-TL1A mAb)","\nPhase 2\n","NCT05668013","A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease","• Crohn Disease\n• Colitis, Ulcerative",216,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 24, 2026\nStudy Completion: March 24, 2026"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT05421598","Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma","• Asthma",446,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 4, 2024\nStudy Completion: March 21, 2025"]
["Immuno-inflammation","itepekimab (anti-IL33 mAb)","\nPhase 2\n","NCT05326412","Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD","• Chronic Obstructive Pulmonary Disease",60,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 1, 2024\nStudy Completion: March 20, 2025"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 3\n","NCT05263206","Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO- CHIC)","• Pruritus",208,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 21, 2025\nStudy Completion: October 3, 2025"]
["Immuno-inflammation","SAR445088 (Complement C1S inhibitor)","\nPhase 2\n","NCT05156710","BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)","• Transplant Rejection",45,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 14, 2024\nStudy Completion: December 3, 2026"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT05131477","Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study","• Eczema\n• Atopic Dermatitis",390,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 15, 2023\nStudy Completion: February 28, 2024"]
["Immuno-inflammation","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT05107115","Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine","• Chronic Spontaneous Urticaria",161,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 19, 2023\nStudy Completion: April 24, 2024"]
["Immuno-inflammation","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT05104892","Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma","• Asthma",196,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: February 6, 2024\nStudy Completion: March 5, 2024"]
["Immuno-inflammation","SAR444656 (IRAK4 degrader)","\nPhase 2\n","NCT06058156","Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis","• Atopic Dermatitis",115,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: April 30, 2026\nStudy Completion: May 28, 2026"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT06033833","Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult\nParticipants With Moderatetosevere Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study","• Asthma",380,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: June 25, 2029\nStudy Completion: June 25, 2029"]
["Immuno-inflammation","SAR444656 (IRAK4 degrader)","\nPhase 2\n","NCT06028230","A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","• Hidradenitis Suppurativa",99,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 17, 2026\nStudy Completion: September 14, 2026"]
["Immuno-inflammation","SAR444336 (Non-beta IL2 Synthorin)","\nPhase 1\n","NCT05876767","Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants","• Healthy Volunteer",76,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Basic Science","Primary Completion: December 12, 2023\nStudy Completion: December 12, 2023"]
["Immuno-inflammation","SAR442970 (anti-TNFa/OX40L Nanobody VHH)","\nPhase 2\n","NCT05849922","A Study to Test the Efficacy and Safety\nof SAR442970 in Adults With Hidradenitis Suppurativa","• Hidradenitis Suppurativa",84,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: October 17, 2024\nStudy Completion: February 7, 2025"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT05769777","Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis","• Dermatitis Atopic",571,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 29, 2027\nStudy Completion: October 29, 2027"]
["Immuno-inflammation","Tzield (anti-CD3 mAb )","\nPhase 4\n","NCT05757713","Teplizumab in Pediatric Stage 2 Type 1 Diabetes","• Type 1 Diabetes",20,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 2026\nStudy Completion: October 2026"]
["Immuno-inflammation","Dupixent (anti-IL4/IL13 mAb) ","\nPhase 2\n","NCT05731128","A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged #18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))","• Colitis Ulcerative",100,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 26, 2024\nStudy Completion: April 14, 2025"]
["Immuno-inflammation","Tzield (anti-CD3 mAb )","\n","NCT04598893","Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab","• Type 1 Diabetes Mellitus",200,"• Observational Model: Cohort\n• Time Perspective: Prospective","Primary Completion: November 2026\nStudy Completion: November 2026"]
["Immuno-inflammation","Tzield (anti-CD3 mAb )","\nPhase 2\n","NCT04270942","At-Risk for Type 1 Diabetes Extension Study","• Diabetes Mellitus, Type 1",30,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: August 2024"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 3\n","NCT06130566","A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 18 Years and Older With Moderate-to- severe Atopic Dermatitis","• Dermatitis Atopic",420,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 9, 2025\nStudy Completion: December 30, 2025"]
["Immuno-inflammation","amlitelimab (anti-OX40L mAb)","\nPhase 2\n","NCT06118099","Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","• Hidradenitis",84,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: March 13, 2025\nStudy Completion: January 14, 2027"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT04270409","A Phase 3 Randomized, Open-label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma","• Plasma Cell Myeloma",320,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 1, 2028\nStudy Completion: October 1, 2033"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT04045795","Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","• Multiple Myeloma",56,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 15, 2024\nStudy Completion: February 15, 2024"]
["Oncology","pegenzileukin (Non-alpha IL2 Synthorin)","\n• Phase 1\n• Phase 2\n","NCT04009681","A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)","• Metastasis",300,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 2026\nStudy Completion: June 2026"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT03733717","Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma","• Multiple Myeloma",25,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 6, 2020\nStudy Completion: August 25, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03617731","Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)","• Multiple Myeloma",662,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 2025\nStudy Completion: December 2025"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03319667","Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant","• Plasma Cell Myeloma",475,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: April 5, 2026\nStudy Completion: June 30, 2027"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT03275285","Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients","• Plasma Cell Myeloma",302,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Single (Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 14, 2022\nStudy Completion: November 19, 2024"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT02990338","Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","• Plasma Cell Myeloma",307,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 22, 2018\nStudy Completion: November 1, 2023"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 1\n","NCT02513186","Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","• Plasma Cell Myeloma",90,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 28, 2022\nStudy Completion: February 9, 2024"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT01084252","Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","• Hematological Malignancy",351,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 21, 2018\nStudy Completion: July 13, 2023"]
["Oncology","pegenzileukin (Non-alpha IL2 Synthorin)","\nPhase 2\n","NCT05179603","A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]","• Classic Hodgkin Lymphoma\n• Diffuse Large B-cell Lymphoma",50,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 14, 2023\nStudy Completion: September 15, 2024"]
["Oncology","pegenzileukin (Non-alpha IL2 Synthorin)","\nPhase 2\n","NCT05104567","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With\nGastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)","• Oesophageal Squamous Cell Carcinoma\n• Gastric Cancer\n• Hepatocellular Carcinoma\n• Colorectal Cancer\n• Oseophageal Adenocarcinoma",280,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 26, 2023\nStudy Completion: March 31, 2024"]
["Oncology","SAR443579 (Trifunctional anti-CD123 NK Cell engager) ","\n• Phase 1\n• Phase 2\n","NCT05086315","First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R\nAML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR- MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","• Acute Lymphocytic Leukaemia\n• Acute Myeloid Leukaemia Refractory\n• Myelodysplastic Syndromes\n• Blastic Plasmacytoid Dendritic Cell Neoplasia",126,"• Allocation: Non-Randomized\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: February 4, 2026\nStudy Completion: January 1, 2027"]
["Oncology","pegenzileukin (Non-alpha IL2 Synthorin)","\nPhase 2\n","NCT05061420","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)","• Squamous Cell Carcinoma of Head and Neck",120,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 21, 2023\nStudy Completion: August 13, 2024"]
["Oncology","pegenzileukin (Non-alpha IL2 Synthorin)","\nPhase 2\n","NCT04914897","A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)","• Pleural Mesothelioma\n• Non-small Cell Lung Cancer",107,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 18, 2023\nStudy Completion: January 22, 2025"]
["Oncology","pegenzileukin (Non-alpha IL2 Synthorin)","\n• Phase 1\n• Phase 2\n","NCT04913220","A Study of SAR444245 Combined With Cemiplimab for the Treatment of\nParticipants With Various Advanced Skin Cancers (Pegathor Skin 201)","• Malignant Melanoma\n• Squamous Cell Carcinoma of Skin",80,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 22, 2023\nStudy Completion: January 27, 2025"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT04751877","Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and\nDexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (# 65; < 80 Years).","• Multiple Myeloma\n• Myeloma",270,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 2, 2024\nStudy Completion: August 17, 2027"]
["Oncology","SAR444881 (anti-ILT2 mAb)","\n• Phase 1\n• Phase 2\n","NCT04717375","Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors","• Cancer\n• Neoplasm",456,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: April 28, 2027\nStudy Completion: April 28, 2027"]
["Oncology","Sarclisa (anti-CD38 mAb)","\n• Phase 1\n• Phase 2\n","NCT04643002","Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","• Plasma Cell Myeloma Refractory",197,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 2, 2027\nStudy Completion: December 2, 2027"]
["Oncology","SAR445419 (NK-cell-based immunotherapy)","\nPhase 1\n","NCT04220684","Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML","• Allogeneic Stem Cell Transplant Recipient\n• Blasts 10 Percent or More of Bone Marrow Nucleated Cells\n• Recurrent Acute Myeloid Leukemia\n• Refractory Acute Myeloid Leukemia",21,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 31, 2023\nStudy Completion: December 31, 2023"]
["Oncology","Rezurock (ROCK2 inhibitor)","\nPhase 3\n","NCT06143891","A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","• Chronic Graft Versus Host Disease",240,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 29, 2028\nStudy Completion: September 29, 2028"]
["Oncology","SAR445953 (anti-CEACAM5-Topo1 ADC)","\nPhase 1\n","NCT06131840","A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","• Colorectal Neoplasms\n• Carcinoma, Non-Small-Cell Lung\n• Stomach Neoplasms\n• Pancreatic Ductal Adenocarcinoma\n• Gastroesophageal Junction Adenocarcinoma\n• Small Cell Lung Carcinoma",410,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 31, 2029\nStudy Completion: March 31, 2030"]
["Oncology","SAR445514 (Trifunctional anti-BCMA NK Cell engager)","\n• Phase 1\n• Phase 2\n","NCT05839626","A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light- chain Amyloidosis (RRLCA)","• Relapsed/Refractory Multiple Myeloma\n• Amyloid Light-chain Amyloidosis",101,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 26, 2026\nStudy Completion: March 30, 2027"]
["Oncology","SAR445419 (NK-cell-based immunotherapy)","\nPhase 1\n","NCT05712278","A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419)\nin Relapsed/Refractory Acute Myeloid Leukemia","• Acute Myeloid Leukaemia",12,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: March 18, 2024\nStudy Completion: February 21, 2025"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 2\n","NCT05704049","A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","• Relapsed/Refractory Multiple Myeloma",68,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 17, 2024\nStudy Completion: November 20, 2026"]
["Oncology","SAR445877 (anti-PD1/IL15 fusion protein)","\n• Phase 1\n• Phase 2\n","NCT05584670","A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","• Solid Tumor",240,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 19, 2027\nStudy Completion: March 15, 2028"]
["Oncology","SAR444200 (anti-GPC3/TCR Nanobody VHH)","\n• Phase 1\n• Phase 2\n","NCT05450562","Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult\nParticipants With Advanced Solid Tumors","• Neoplasm",106,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 12, 2030\nStudy Completion: December 12, 2030"]
["Oncology","Sarclisa (anti-CD38 mAb)","\nPhase 3\n","NCT05405166","SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","• Plasma Cell Myeloma Recurrent",534,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 23, 2024\nStudy Completion: February 15, 2027"]
["Oncology","SAR446309 (HER2 T-Cell engager)","\nPhase 1\n","NCT05356741","To Access the Safety and Effects of Intravenous Administration of\nAMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2- Expressing Cancers","• Locally Advanced or Metastatic HER2-Expressing Cancers",575,"• Allocation: Non-Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 9, 2026\nStudy Completion: December 9, 2026"]
["Neurology","frexalimab (anti-CD40L mAb)","\nPhase 3\n","NCT06141473","Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis","• Multiple Sclerosis",1400,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 6, 2027\nStudy Completion: May 6, 2027"]
["Neurology","SAR443820 (RIPK1 inhibitor central)","\nPhase 2\n","NCT05630547","A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis","• Multiple Sclerosis",174,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 3, 2025\nStudy Completion: September 3, 2025"]
["Neurology","SAR443820 (RIPK1 inhibitor central)","\nPhase 2\n","NCT05237284","Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)","• Amyotrophic Lateral Sclerosis",305,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: July 17, 2024\nStudy Completion: January 8, 2027"]
["Neurology","frexalimab (anti-CD40L mAb)","\nPhase 2\n","NCT04879628","Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis","• Multiple Sclerosis",129,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 21, 2022\nStudy Completion: April 30, 2024"]
["Neurology","SAR445088 (Complement C1S inhibitor)","\nPhase 2\n","NCT04658472","Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","• Chronic Inflammatory Demyelinating Polyradiculoneuropathy",110,"• Allocation: Non-Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: August 25, 2025\nStudy Completion: August 25, 2025"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04458051","Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)","• Primary Progressive Multiple Sclerosis",700,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 31, 2024\nStudy Completion: August 31, 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Secondary Progressive Multiple Sclerosis",1131,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: August 2024\nStudy Completion: August 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04410991","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Relapsing Multiple Sclerosis",900,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: April 30, 2024\nStudy Completion: April 30, 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 3\n","NCT04410978","Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","• Relapsing Multiple Sclerosis",900,"\n \n• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: April 30, 2024\nStudy Completion: April 30, 2024"]
["Neurology","tolebrutinub (BTK inhibitor)","\nPhase 2\n","NCT03996291","Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis","• Relapsing Multiple Sclerosis",125,"\n \n• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 29, 2024\nStudy Completion: November 29, 2024"]
["Neurology","frexalimab (anti-CD40L mAb)","\nPhase 3\n","NCT06141486","Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis","• Multiple Sclerosis",858,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: December 23, 2026\nStudy Completion: March 24, 2028"]
["Neurology","SAR446159 (anti-Synuclein/IGF1R mAb)","\nPhase 1\n","NCT05756920","This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants","• Healthy",40,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 21, 2023\nStudy Completion: September 21, 2023"]
["Rare diseases","SAR442501 (anti-FGFR3 Ab)","\nPhase 2\n","NCT06067425","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia","• Osteochondrodysplasia",36,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 2, 2027\nStudy Completion: December 2, 2027"]
["Rare diseases","SAR444836 (PAH replacement AAV-based gene therapy)","\n• Phase 1\n• Phase 2\n","NCT05972629","A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria","• Phenylketonuria",32,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: July 2027\nStudy Completion: July 2027"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT05280548","A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease","• Fabry Disease",90,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: December 29, 2025\nStudy Completion: July 14, 2027"]
["Rare diseases","SAR439459 (anti-TGFb mAb)","\nPhase 1\n","NCT05231668","Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)","• Osteogenesis Imperfecta",24,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Triple (Participant, Care Provider, Investigator)\n• Primary Purpose: Treatment","Primary Completion: June 30, 2025\nStudy Completion: June 30, 2025"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT05222906","Study to Evaluate the Efficacy and Safety\nof Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3","• Gaucher's Disease Type III",40,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: September 30, 2025\nStudy Completion: October 30, 2026"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT05206773","A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants #16 Years of Age With Fabry Disease","• Fabry Disease",114,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Treatment","Primary Completion: November 30, 2024\nStudy Completion: July 8, 2026"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 3\n","NCT04221451","A Multinational, Randomized, Double- blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics,\nPharmacokinetics, and Safety of Venglustat in Late-onset GM2","• Tay-Sachs Disease\n• Sandhoff Disease",75,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: January 19, 2024\nStudy Completion: February 25, 2026"]
["Rare diseases","Nexviazyme (Enzyme Replacement Therapy - GAA) ","\nPhase 2\n","NCT03019406","A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa","• Glycogen Storage Disease Type II-Pompe's Disease",22,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 30, 2019\nStudy Completion: June 15, 2026"]
["Rare diseases","venglustat (oral GCS inhibitor) ","\nPhase 2\n","NCT02843035","Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","• Gaucher Disease Type 1\n• Gaucher Disease Type 3",12,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: September 30, 2025\nStudy Completion: September 30, 2025"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\nPhase 2\n","NCT05002777","Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)","• Warm Autoimmune Hemolytic Anemia (wAIHA)",22,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: May 29, 2024\nStudy Completion: May 28, 2025"]
["Rare blood disorders","SAR445088 (Complement C1S inhibitor)","\nPhase 1\n","NCT04802057","Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088","• Autoimmune Haemolytic Anaemia",9,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: June 16, 2028\nStudy Completion: June 16, 2028"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\nPhase 3\n","NCT04562766","Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia",194,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: June 5, 2025\nStudy Completion: November 20, 2026"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\n• Phase 2\n• Phase 3\n","NCT03974113","Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B","• Hemophilia",37,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: October 31, 2024\nStudy Completion: December 27, 2024"]
["Rare blood disorders","fitusiran (RNAi targeting anti-thrombin)  ","\nPhase 3\n","NCT03754790","Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX","• Hemophilia",281,"• Allocation: N/A\n• Intervention Model: Single Group Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: November 5, 2026\nStudy Completion: November 5, 2026"]
["Rare blood disorders","rilzabrutinib (BTK inhibitor)","\n• Phase 1\n• Phase 2\n","NCT03395210","A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)","• Immune Thrombocytopenia\n• Immune Thrombocytopenic Purpura",81,"• Allocation: N/A\n• Intervention Model: Sequential Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Treatment","Primary Completion: January 31, 2023\nStudy Completion: December 2025"]
["Vaccines","SP0202 (21-valent Pneumococcal conjugate  vaccine)","\nPhase 2\n","NCT04398706","Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","• Pneumococcal Immunisation\n• Diphtheria Immunisation\n• Tetanus Immunisation\n• Pertussis Immunisation\n• Hepatitis B Immunisation\n• Haemophilus Influenzae Type b Immunisation\n• Polio Immunisation\n• Measles Immunisation\n• Rubella Immunisation\n• Varicella Immunisation\n• Mumps Immunisation",853,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: August 10, 2023\nStudy Completion: August 10, 2023"]
["Vaccines","MenQuadfi (Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT04143061","Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","• Healthy Volunteers (Meningococcal Infection)",1328,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: January 28, 2023\nStudy Completion: January 28, 2023"]
["Vaccines","MenQuadfi (Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT04142242","Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","• Meningococcal Infection (Healthy Volunteers)",471,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: April 1, 2020\nStudy Completion: May 25, 2022"]
["Vaccines","SP0087 (Purified vero rabies vaccine)","\nPhase 3\n","NCT04127786","Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults","• Rabies (Healthy Volunteers)",1700,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: March 25, 2020\nStudy Completion: May 12, 2025"]
["Vaccines","MenQuadfi (Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT03691610","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","• Healthy Volunteers (Meningococcal Infection)",1070,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: October 28, 2024\nStudy Completion: October 28, 2024"]
["Vaccines","MenQuadfi (Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT03547271","Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","• Meningococcal Infections",1660,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: May 17, 2023\nStudy Completion: May 17, 2023"]
["Vaccines","MenQuadfi (Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT03537508","Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","• Healthy Volunteers (Meningococcal Infection)",2637,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: September 22, 2023\nStudy Completion: September 22, 2023"]
["Vaccines","SP0256 (mRNA RSV Combination Vaccine)","\n• Phase 1\n• Phase 2\n","NCT06134648","Study of a Respiratory Syncytial Virus/ Human Metapneumovirus Vaccine Candidate","• Respiratory Syncytial Virus Infection\n• Healthy Volunteers\n• Human Metapneumovirus",210,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: March 10, 2026\nStudy Completion: March 10, 2026"]
["Vaccines","SP0230 (Meningococcal ABCYW conjugate vaccine)","\n• Phase 1\n• Phase 2\n","NCT06128733","Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","• Meningococcal Infection\n• Healthy Volunteers",1120,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: May 22, 2025\nStudy Completion: May 22, 2025"]
["Vaccines","SP0273 (mRNA QIV)","\nPhase 1\n","NCT05829356","Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","• Influenza Immunization",159,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Prevention","Primary Completion: February 23, 2024\nStudy Completion: February 23, 2024"]
["Vaccines","MenQuadfi (Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT05794230","Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","• Meningococcal Immunisation\n• Healthy Volunteers",1528,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: September 8, 2025\nStudy Completion: September 8, 2025"]
["Vaccines","SP0125 (Live-Attenuated RSV Vaccine)","\n• Phase 1\n• Phase 2\n","NCT05687279","Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic\nStability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)","• Respiratory Syncytial Virus Infection",100,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: January 23, 2025\nStudy Completion: January 23, 2025"]
["Vaccines","SP0256 (mRNA RSV Vaccine)","\n• Phase 1\n• Phase 2\n","NCT05639894","Study of a Respiratory Syncytial Virus mRNA Candidate With 2 Different Lipid Nanoparticle-based Formulations in Adults Aged 18 to 50 Years and 60 Years and Older","• Respiratory Syncytial Virus Immunization",790,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: April 6, 2023\nStudy Completion: April 30, 2026"]
["Vaccines","SP0273 (mRNA QIV Vaccine)","\n• Phase 1\n• Phase 2\n","NCT05553301","Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","• Influenza Immunization",560,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Triple (Participant, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: January 19, 2024\nStudy Completion: January 19, 2024"]
["Vaccines","SP0282 (Extraintestinal Pathogenic E. Coli Vaccine ExPEC9V)","\nPhase 3\n","NCT04899336","A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic\nEscherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years","• Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention",18556,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Double (Participant, Investigator)\n• Primary Purpose: Prevention","Primary Completion: May 19, 2025\nStudy Completion: May 14, 2028"]
["Vaccines","SP0218 (Yellow fever vaccine)","\nPhase 2\n","NCT04942210","Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA","• Yellow Fever (Healthy Volunteers)",567,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Prevention","Primary Completion: June 24, 2022\nStudy Completion: June 29, 2028"]
["Vaccines","MenQuadfi (Meningococcal ACYW conjugate vaccine)","\nPhase 3\n","NCT04936685","Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers","• Meningococcal Immunisation (Healthy Volunteers)",166,"• Allocation: Randomized\n• Intervention Model: Parallel Assignment\n• Masking: None (Open Label)\n• Primary Purpose: Prevention","Primary Completion: March 9, 2023\nStudy Completion: December 26, 2027"]
["Vaccines","SP0230 (Multicomponent Meningococcal vaccine)","\n• Phase 1\n• Phase 2\n","NCT04825223","Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","• Meningococcal Immunisation",576,"• Allocation: Randomized\n• Intervention Model: Sequential Assignment\n• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\n• Primary Purpose: Treatment","Primary Completion: May 5, 2026\nStudy Completion: May 5, 2026"]